bioMerieux Gains Oncology and Theranostics Capabilities with the Acquisition of AviaraDx
News Sep 12, 2008
bioMerieux has acquired the privately held AviaraDx, Inc., a molecular in vitro diagnostics company, based in San Diego, California (USA). AviaraDx’s diagnostic tests, based on their proprietary technologies, are used in the molecular classification of cancers and to assist oncologists in making critical therapeutic decisions.
The company has built a molecular R&D lab and a small sales & marketing team, as well as a high complexity Clinical Laboratory Improvement Amendments (CLIA) certified service lab.
bioMerieux’s strategy focuses on infectious diseases and high medical-value diagnostic tests, and for the latter, theranostics and oncology are critical elements. With AviaraDx, bioMerieux gains validated cancer biomarkers as well as capabilities in gene expression profiling in tissues for applications in oncology.
AviaraDx has two innovative products on the market based on proprietary technologies: Aviara CancerTYPE ID® provides improved cancer classification, especially for patients diagnosed with metastatic cancer where the origin is uncertain or unknown.
Aviara Breast Cancer IndexSM offers a combined assessment of two Aviara markers (H/I and MGI) for risk prognosis and treatment response prediction for chemo and hormonal therapy. AviaraDx‘s high complexity CLIA certified service lab makes these diagnostic tests widely available to physicians in the U.S.
bioMerieux is thus in a position to offer a wide range of high-value tools for cancer management, which help oncologists make relevant clinical decisions in their daily practice: the widely installed VIDAS® immunoassay platform and molecular diagnostics with the NucliSENS® range and AviaraDx technologies.
“The acquisition of AviaraDx is a major milestone in bioMerieux’s long-term growth strategy. Their molecular technology in tumor tissue and broad clinical capabilities will help us achieve Dr. Christophe Merieux’s vision of providing patients with personalized, predictive medicine,” stated Stephane Bancel, Chief Executive Officer of bioMerieux. “We are also very excited to welcome the talented AviaraDx team to bioMerieux,” he added.
bioMerieux acquired full ownership of AviaraDx for $60 million. The company plans to keep AviaraDx as an independent legal entity called bioTheranostics, Inc. Richard Ding, bioMerieux’s Corporate Vice President of Business Development and Theranostics, has been named Chief Executive Officer of bioTheranostics. He will also continue to serve as a member of the bioMerieux Management Committee and to lead bioMerieux’s business development and theranostics activities.
2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry
May 30 - May 31, 2019